Cabaletta Bio (CABA) reported a net loss of $51.0 million, or $0.34 per basic and diluted share, for the second quarter ended June 30, 2026. Research and development expense was $44.4 million, while general and administrative expense was $7.6 million.
The company ended the quarter with $225.1 million in cash, cash equivalents and short-term investments and said the balance is expected to fund operations into mid-2027. Cabaletta continues to target mid-2027 for registrational RESET-Myositis data and a potential BLA submission in the second half of 2027.
- Cash, cash equivalents and short-term investments were $225.1 million as of June 30, 2026, compared with $133.6 million at December 31, 2025.
- RESET-SSc enrollment for approximately 25 patients with SSc-associated interstitial lung disease is anticipated to begin in the fourth quarter of 2026.
- Cabaletta selected ElevateBio as a second CDMO for clinical and commercial manufacturing of rese-cel, alongside Lonza.
- The company is incorporating a preconditioning-free approach into RESET-MG and advancing higher-dose cohorts in RESET-PV and RESET-SLE.
$CABA Hedge Fund Activity
We have seen 80 institutional investors add shares of $CABA stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC added 11,063,152 shares (+123.3%) to their portfolio in Q2 2026, for an estimated $34,406,402
- BLACKROCK, INC. added 8,381,698 shares (+353.2%) to their portfolio in Q2 2026, for an estimated $26,067,080
- STATE STREET CORP added 7,369,327 shares (+1568.0%) to their portfolio in Q2 2026, for an estimated $22,918,606
- NORGES BANK added 4,112,401 shares (+inf%) to their portfolio in Q2 2026, for an estimated $12,789,567
- MILLENNIUM MANAGEMENT LLC added 3,166,369 shares (+115.7%) to their portfolio in Q1 2026, for an estimated $8,517,532
- GEODE CAPITAL MANAGEMENT, LLC added 2,326,219 shares (+205.3%) to their portfolio in Q2 2026, for an estimated $7,234,541
- QUBE RESEARCH & TECHNOLOGIES LTD added 1,603,765 shares (+484.2%) to their portfolio in Q1 2026, for an estimated $4,314,127
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
